# Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy

> **NCT02223182** · PHASE1,PHASE2 · COMPLETED · sponsor: **DBV Technologies** · enrollment: 198 (actual)

## Conditions studied

- Food Allergy

## Interventions

- **BIOLOGICAL:** Viaskin Milk 150 mcg
- **BIOLOGICAL:** Viaskin Milk 300 mcg
- **BIOLOGICAL:** Viaskin Milk 500 mcg
- **BIOLOGICAL:** Viaskin Placebo

## Key facts

- **NCT ID:** NCT02223182
- **Lead sponsor:** DBV Technologies
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-11
- **Primary completion:** 2017-12-14
- **Final completion:** 2020-12-22
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2024-11-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02223182

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02223182, "Efficacy and Safety of Viaskin Milk in Children With IgE-Mediated Cow's Milk Allergy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02223182. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*